iBio Highlights Data from a Non-human Primate Study Supporting IBIO-610’s Potential to Preserve Muscle in Combination with GLP-1 Therapy
Globe Newswire•13/10/2026•07:00 ET
0
Key Highlights
- ➤93% of IBIO-610 plus semaglutide weight loss was fat, versus 77% with semaglutide alone
- ➤iBio expects first-in-human IBIO-610 trials to begin in first half of 2027
- ➤IBIO-610 reduced serum active Activin E levels 97% at week eight
- ➤IBIO-610 showed a 33.2-day NHP half-life, potentially supporting twice-yearly human dosing
Expert Statements
Martin Brenner, DVM, Ph.D., Chief Executive Officer and Chief Scientific Officer of iBio
“While GLP-1 therapies have transformed obesity care, patients still need additional options to improve the quality of weight loss.”
Martin Brenner, DVM, Ph.D., Chief Executive Officer and Chief Scientific Officer of iBio
“In this NHP study, IBIO-610 delivered durable, near-complete inhibition of active Activin E, and when combined with semaglutide, nearly all observed weight loss came from fat.”
Martin Brenner, DVM, Ph.D., Chief Executive Officer and Chief Scientific Officer of iBio
“We plan to begin first-in-human studies in the first half of 2027.”
Martin Brenner, DVM, Ph.D., Chief Executive Officer and Chief Scientific Officer of iBio
“Our focus is on translating this biology into a potential new therapeutic option for patients living with obesity and cardiometabolic disease.”
In an eight-week obese NHP study, lean mass made up 6% of weight lost with IBIO-610, an Activin E antibody, plus semaglutide, versus 22% with semaglutide alone
iBio expects to start first-in-human trials of IBIO-610 in first half of 2027
Get started
Create a free account to read the full story.